About Penumbra (NYSE:PEN)
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:PEN
CUSIPN/A
Phone510-748-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio7.41%
Quick Ratio5.57%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio891.07
P/E Growth45.53
Sales & Book Value
Annual Sales$333.76 million
Price / Sales12.76
Cash Flow$0.1225 per share
Price / Cash1,018.73
Book Value$11.80 per share
Price / Book10.57
Profitability
EPS (Most Recent Fiscal Year)($0.01)
Net Income$4.65 million
Net Margins1.40%
Return on Equity-0.23%
Return on Assets-0.20%
Miscellaneous
Employees1,700
Outstanding Shares34,130,000
Penumbra (NYSE:PEN) Frequently Asked Questions
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra (NYSE:PEN) issued its quarterly earnings data on Tuesday, February, 27th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.11. The firm earned $96.05 million during the quarter, compared to analysts' expectations of $87.69 million. Penumbra had a net margin of 1.40% and a negative return on equity of 0.23%. View Penumbra's Earnings History.
What price target have analysts set for PEN?
6 Wall Street analysts have issued 12-month target prices for Penumbra's stock. Their predictions range from $115.00 to $145.00. On average, they expect Penumbra's stock price to reach $130.75 in the next twelve months. View Analyst Ratings for Penumbra.
What are Wall Street analysts saying about Penumbra stock?
Here are some recent quotes from research analysts about Penumbra stock:
- 1. Canaccord Genuity analysts commented, "We would stay buyers of PEN, which continues to be a top pick in S/Mid-cap med-tech. We picked up notable legislative progress out of Tennessee both noteworthy and positive for PEN as well as the AIS market in general." (4/5/2018)
- 2. According to Zacks Investment Research, "Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. " (1/17/2018)
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include Dexcom (DXCM), Hill-Rom (HRC), Insulet (PODD), ICU Medical (ICUI), Globus Medical (GMED), Cantel Medical (CMD), Haemonetics (HAE), Nevro (NVRO), NuVasive (NUVA), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR) and Glaukos (GKOS).
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Mr. Adam Elsesser, Co Founder, Chairman, Chief Exec. Officer and Pres (Age 56)
- Dr. Arani Bose M.D., Co-Founder, Chief Innovator and Director (Age 56)
- Mr. Sridhar N. Kosaraju, Chief Financial Officer and Head of Strategy (Age 40)
- Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 57)
- Mr. Daniel Donen Davis, Chief Commercial Officer & Pres of North America (Age 40)
Has Penumbra been receiving favorable news coverage?
News headlines about PEN stock have been trending positive recently, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Penumbra earned a news sentiment score of 0.36 on Accern's scale. They also assigned press coverage about the company an impact score of 45.67 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Penumbra?
Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of PEN stock can currently be purchased for approximately $124.75.
How big of a company is Penumbra?
Penumbra has a market capitalization of $4.27 billion and generates $333.76 million in revenue each year. The company earns $4.65 million in net income (profit) each year or ($0.01) on an earnings per share basis. Penumbra employs 1,700 workers across the globe.
How can I contact Penumbra?
Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]
MarketBeat Community Rating for Penumbra (PEN)
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Penumbra (NYSE:PEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Penumbra in the last 12 months. Their average twelve-month price target is $130.75, suggesting that the stock has a possible upside of 4.81%. The high price target for PEN is $145.00 and the low price target for PEN is $115.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Buy |
| Consensus Rating Score: | 2.67 | 2.60 | 2.33 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $130.75 | $126.00 | $111.50 | $98.00 |
| Price Target Upside: | 4.81% upside | 4.05% upside | 18.49% upside | 6.99% upside |
Penumbra (NYSE:PEN) Consensus Price Target History
Penumbra (NYSE:PEN) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Penumbra (NYSE:PEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Penumbra (NYSE PEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.50%
Institutional Ownership Percentage: 73.42%
Penumbra (NYSE PEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | Lynn Rothman | EVP | Sell | 6,000 | $125.02 | $750,120.00 | 144,319 |  |
| 3/12/2018 | Robert D Evans | EVP | Sell | 10,000 | $121.03 | $1,210,300.00 | 12,225 | |
| 3/6/2018 | Lynn Rothman | EVP | Sell | 3,727 | $115.01 | $428,642.27 | 153,155 | |
| 2/28/2018 | Lynn Rothman | EVP | Sell | 2,273 | $115.00 | $261,395.00 | 154,046 | |
| 1/29/2018 | Don W Kassing | Director | Sell | 2,000 | $100.94 | $201,880.00 | 2,648 | |
| 1/16/2018 | Daniel Donen Davis | Insider | Sell | 30,000 | $88.80 | $2,664,000.00 | | |
| 1/16/2018 | Lynn Rothman | EVP | Sell | 6,000 | $90.99 | $545,940.00 | 159,519 | |
| 1/2/2018 | Robert D Evans | EVP | Sell | 40,000 | $89.89 | $3,595,600.00 | 11,704 | |
| 1/2/2018 | Thomas Wilder | Director | Sell | 345 | $91.15 | $31,446.75 | | |
| 11/28/2017 | Adam Elsesser | CEO | Sell | 10,000 | $103.95 | $1,039,500.00 | 1,121,356 | |
| 11/28/2017 | Arani Bose | Insider | Sell | 10,927 | $103.96 | $1,135,970.92 | 639,527 | |
| 11/28/2017 | Sridhar Kosaraju | CFO | Sell | 6,026 | $103.83 | $625,679.58 | | |
| 11/24/2017 | Adam Elsesser | CEO | Sell | 10,135 | $105.10 | $1,065,188.50 | 1,133,672 | |
| 11/24/2017 | James Robert Pray | Insider | Sell | 5,088 | $105.26 | $535,562.88 | 523,894 | |
| 11/24/2017 | Sridhar Kosaraju | CFO | Sell | 4,818 | $105.10 | $506,371.80 | | |
| 11/22/2017 | Adam Elsesser | CEO | Sell | 5,051 | $105.98 | $535,304.98 | 1,133,672 | |
| 11/22/2017 | Arani Bose | Insider | Sell | 6,248 | $106.10 | $662,912.80 | 652,118 | |
| 11/22/2017 | Sridhar Kosaraju | CFO | Sell | 2,600 | $105.99 | $275,574.00 | | |
| 11/21/2017 | Bridget O'rourke | Director | Sell | 429 | $106.60 | $45,731.40 | | |
| 11/20/2017 | Adam Elsesser | CEO | Sell | 62,862 | $105.15 | $6,609,939.30 | 1,191,887 | |
| 11/20/2017 | Arani Bose | Insider | Sell | 47,136 | $105.15 | $4,956,350.40 | 700,815 | |
| 11/20/2017 | Sridhar Kosaraju | CFO | Sell | 21,956 | $105.27 | $2,311,308.12 | | |
| 11/17/2017 | Adam Elsesser | CEO | Sell | 11,186 | $103.56 | $1,158,422.16 | 1,191,887 | |
| 11/17/2017 | Arani Bose | Insider | Sell | 8,133 | $103.50 | $841,765.50 | 700,815 | |
| 11/17/2017 | Sridhar Kosaraju | CFO | Sell | 4,290 | $103.52 | $444,100.80 | | |
| 11/15/2017 | Adam Elsesser | CEO | Sell | 24,444 | $105.83 | $2,586,908.52 | 1,231,338 | |
| 11/15/2017 | Arani Bose | Insider | Sell | 16,452 | $105.89 | $1,742,102.28 | 728,680 | |
| 11/15/2017 | Sridhar Kosaraju | CFO | Sell | 10,900 | $105.89 | $1,154,201.00 | | |
| 10/5/2017 | Harpreet Grewal | Director | Sell | 500 | $92.90 | $46,450.00 | | |
| 10/2/2017 | Thomas Wilder | Director | Sell | 345 | $90.20 | $31,119.00 | | |
| 9/29/2017 | Robert D Evans | EVP | Sell | 20,017 | $90.03 | $1,802,130.51 | 11,704 | |
| 9/28/2017 | Robert D Evans | EVP | Sell | 2,108 | $90.00 | $189,720.00 | 11,704 | |
| 9/27/2017 | Robert D Evans | EVP | Sell | 1,586 | $90.00 | $142,740.00 | 11,704 | |
| 9/21/2017 | Robert D Evans | EVP | Sell | 4,983 | $90.00 | $448,470.00 | 11,704 | |
| 9/20/2017 | Robert D Evans | EVP | Sell | 2,859 | $90.00 | $257,310.00 | 11,704 | |
| 8/21/2017 | Harpreet Grewal | Director | Sell | 4,500 | $82.65 | $371,925.00 | | |
| 8/9/2017 | Robert D Evans | EVP | Sell | 10,000 | $85.15 | $851,500.00 | 11,704 | |
| 8/1/2017 | Daniel Donen Davis | Insider | Sell | 32,000 | $79.42 | $2,541,440.00 | | |
| 7/18/2017 | Thomas Wilder | Director | Sell | 345 | $86.10 | $29,704.50 | | |
| 4/24/2017 | Robert D Evans | EVP | Sell | 10,000 | $85.24 | $852,400.00 | 12,075 | |
| 2/14/2017 | Robert D Evans | EVP | Sell | 5,000 | $75.00 | $375,000.00 | 7,075 | |
| 2/13/2017 | Adam Elsesser | CEO | Sell | 7,700 | $72.21 | $556,017.00 | 1,241,938 | |
| 2/13/2017 | James Robert Pray | Insider | Sell | 1,700 | $73.04 | $124,168.00 | 543,778 | |
| 2/13/2017 | Sridhar Kosaraju | CFO | Sell | 1,600 | $72.94 | $116,704.00 | | |
| 2/10/2017 | James Robert Pray | Insider | Sell | 23,900 | $71.08 | $1,698,812.00 | 566,978 | |
| 2/10/2017 | Sridhar Kosaraju | CFO | Sell | 15,500 | $71.49 | $1,108,095.00 | | |
| 2/9/2017 | Arani Bose | Insider | Sell | 22,300 | $70.44 | $1,570,812.00 | 736,191 | |
| 2/9/2017 | Lynn Rothman | EVP | Sell | 2,700 | $70.20 | $189,540.00 | | |
| 2/7/2017 | James Robert Pray | Insider | Sell | 4,099 | $69.09 | $283,199.91 | 575,178 | |
| 2/7/2017 | Robert D Evans | EVP | Sell | 1 | $70.00 | $70.00 | 7,075 | |
| 2/6/2017 | Arani Bose | Insider | Sell | 17,100 | $70.01 | $1,197,171.00 | 736,691 | |
| 2/6/2017 | Lynn Rothman | EVP | Sell | 2,886 | $70.41 | $203,203.26 | | |
| 2/6/2017 | Sridhar Kosaraju | CFO | Sell | 100 | $70.00 | $7,000.00 | | |
| 2/3/2017 | James Robert Pray | Insider | Sell | 15,600 | $70.39 | $1,098,084.00 | 590,159 | |
| 2/3/2017 | Robert D Evans | EVP | Sell | 5,000 | $70.35 | $351,750.00 | 7,075 | |
| 2/3/2017 | Sridhar Kosaraju | CFO | Sell | 7,800 | $70.56 | $550,368.00 | | |
| 2/1/2017 | Adam Elsesser | CEO | Sell | 21,400 | $70.98 | $1,518,972.00 | 1,244,038 | |
| 2/1/2017 | Daniel Donen Davis | Insider | Sell | 7,298 | $71.00 | $518,158.00 | | |
| 2/1/2017 | Lynn Rothman | EVP | Sell | 4,414 | $70.99 | $313,349.86 | | |
| 1/31/2017 | Adam Elsesser | CEO | Sell | 9,000 | $71.26 | $641,340.00 | 1,244,038 | |
| 1/31/2017 | Daniel Donen Davis | Insider | Sell | 3,000 | $71.29 | $213,870.00 | | |
| 1/31/2017 | Lynn Rothman | EVP | Sell | 1,800 | $71.27 | $128,286.00 | | |
| 1/30/2017 | Adam Elsesser | CEO | Sell | 8,200 | $70.72 | $579,904.00 | 1,244,038 | |
| 1/30/2017 | Daniel Donen Davis | Insider | Sell | 2,698 | $70.71 | $190,775.58 | | |
| 1/30/2017 | Lynn Rothman | EVP | Sell | 1,700 | $70.79 | $120,343.00 | | |
| 1/27/2017 | Arani Bose | Insider | Sell | 31,500 | $74.12 | $2,334,780.00 | 748,691 | |
| 1/27/2017 | Lynn Rothman | EVP | Sell | 7,000 | $74.24 | $519,680.00 | | |
| 1/26/2017 | Don W Kassing | Director | Sell | 3,000 | $74.50 | $223,500.00 | 2,666 | |
| 11/16/2016 | Sridhar Kosaraju | CFO | Sell | 25,000 | $65.07 | $1,626,750.00 | | |
| 9/9/2016 | Adam Elsesser | CEO | Sell | 57,200 | $71.07 | $4,065,204.00 | 1,249,838 | |
| 9/6/2016 | Arani Bose | Insider | Sell | 61,000 | $70.72 | $4,313,920.00 | 742,891 | |
| 9/2/2016 | Robert D Evans | EVP | Sell | 3,100 | $70.10 | $217,310.00 | 2,538 | |
| 8/31/2016 | Adam Elsesser | CEO | Sell | 26,000 | $71.15 | $1,849,900.00 | 1,244,838 | |
| 8/31/2016 | Robert D Evans | EVP | Sell | 5,300 | $71.17 | $377,201.00 | 2,538 | |
| 8/26/2016 | Adam Elsesser | CEO | Sell | 26,800 | $71.06 | $1,904,408.00 | 1,244,638 | |
| 8/26/2016 | Robert D Evans | EVP | Sell | 5,300 | $71.03 | $376,459.00 | 2,538 | |
| 8/24/2016 | Adam Elsesser | CEO | Sell | 29,000 | $72.95 | $2,115,550.00 | 1,245,938 | |
| 8/24/2016 | Robert D Evans | EVP | Sell | 6,300 | $73.00 | $459,900.00 | 2,538 | |
| 5/23/2016 | Robert D Evans | EVP | Sell | 5,000 | $50.52 | $252,600.00 | 2,538 | |
| 5/19/2016 | Don W Kassing | Director | Sell | 3,000 | $48.63 | $145,890.00 | 4,000 | |
| 5/19/2016 | Robert D Evans | EVP | Buy | 1,538 | $25.50 | $39,219.00 | 2,538 | |
| 5/16/2016 | James Robert Pray | Insider | Sell | 32,500 | $48.51 | $1,576,575.00 | 631,770 | |
(Data available from 1/1/2013 forward)
Penumbra (NYSE PEN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Penumbra, Inc. Schedules First Quarter 2018 Earnings Release and Conference Call for May 8, 2018
finance.yahoo.com - April 18 at 4:54 PM |
 | Penumbra (PEN) versus Its Competitors Financial Analysis
www.americanbankingnews.com - April 16 at 7:07 PM |
| Penumbra (PEN) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 5:24 PM |
| Penumbra Inc (PEN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 8:49 AM |
| Penumbra Inc (PEN) Expected to Announce Quarterly Sales of $92.57 Million
www.americanbankingnews.com - April 12 at 1:48 AM |
| Brokerages Expect Penumbra Inc (PEN) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - April 10 at 11:21 PM |
| Penumbra's (PEN) Buy Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - April 5 at 1:57 PM |
| Penumbra (PEN) Research Coverage Started at Goldman Sachs
www.americanbankingnews.com - April 4 at 8:04 AM |
| Penumbra (PEN) PT Raised to $117.00
www.americanbankingnews.com - April 1 at 9:11 AM |
| Penumbra (PEN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:48 PM |
| $92.57 Million in Sales Expected for Penumbra Inc (PEN) This Quarter
www.americanbankingnews.com - March 26 at 1:50 AM |
| Analysts Anticipate Penumbra Inc (PEN) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - March 24 at 11:16 PM |
| Head-To-Head Contrast: Penumbra (PEN) vs. Its Peers
www.americanbankingnews.com - March 22 at 3:24 PM |
| With A -68.56% Earnings Drop, Did Penumbra Inc (NYSE:PEN) Really Underperform?
finance.yahoo.com - March 20 at 9:27 AM |
| Insider Selling: Penumbra Inc (PEN) EVP Sells 6,000 Shares of Stock
www.americanbankingnews.com - March 19 at 7:28 PM |
| Wells Fargo Boosts Penumbra (PEN) Price Target to $138.00
www.americanbankingnews.com - March 18 at 11:14 AM |
| Penumbra Inc (PEN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 18 at 8:54 AM |
| Robert D. Evans Sells 10,000 Shares of Penumbra Inc (PEN) Stock
www.americanbankingnews.com - March 14 at 7:12 PM |
| What Should We Expect From Penumbra Inc’s (NYSE:PEN) Earnings In The Year Ahead?
finance.yahoo.com - March 12 at 5:43 PM |
 | Form 4 Penumbra Inc For: Mar 05 Filed by: Rothman Lynn
www.streetinsider.com - March 8 at 9:32 AM |
| Lynn Rothman Sells 3,727 Shares of Penumbra Inc (PEN) Stock
www.americanbankingnews.com - March 8 at 12:30 AM |
| -$0.02 Earnings Per Share Expected for Penumbra Inc (PEN) This Quarter
www.americanbankingnews.com - March 7 at 5:29 PM |
| Penumbra Inc (PEN) Shares Sold by Next Century Growth Investors LLC
www.americanbankingnews.com - March 3 at 3:54 PM |
| Penumbra Inc (PEN) Stake Increased by OppenheimerFunds Inc.
www.americanbankingnews.com - March 3 at 10:34 AM |
| Insider Selling: Penumbra Inc (PEN) EVP Sells 2,273 Shares of Stock
www.americanbankingnews.com - March 2 at 9:20 PM |
| Swiss National Bank Raises Holdings in Penumbra Inc (PEN)
www.americanbankingnews.com - March 2 at 7:32 PM |
| Penumbra Inc Expected to Post FY2018 Earnings of $0.10 Per Share (PEN)
www.americanbankingnews.com - March 2 at 2:10 PM |
| EAM Investors LLC Has $1.83 Million Stake in Penumbra Inc (PEN)
www.americanbankingnews.com - March 2 at 1:05 PM |
| Penumbra Inc (PEN) to Post Q3 2018 Earnings of $0.04 Per Share, William Blair Forecasts
www.americanbankingnews.com - March 1 at 10:21 AM |
| Penumbra Inc (PEN) Shares Sold by First Republic Investment Management Inc.
www.americanbankingnews.com - March 1 at 9:12 AM |
| Penumbra, Inc. (PEN) Reports Q4 EPS of $0.25, Beats on Revenues; Offers FY18 Revenue Guidance Above Estimates
www.streetinsider.com - March 1 at 8:59 AM |
| Canaccord Genuity Reaffirms "Buy" Rating for Penumbra (PEN)
www.americanbankingnews.com - February 28 at 11:22 PM |
| BMO Capital Markets Raises Penumbra (PEN) Price Target to $115.00
www.americanbankingnews.com - February 28 at 5:14 PM |
| Wells Fargo & Co Increases Penumbra (PEN) Price Target to $125.00
www.americanbankingnews.com - February 28 at 4:27 PM |
| Penumbra Inc (PEN) Holdings Trimmed by Champlain Investment Partners LLC
www.americanbankingnews.com - February 28 at 12:58 PM |
| Penumbra beats Street 4Q forecasts
finance.yahoo.com - February 28 at 9:09 AM |
| Penumbra (PEN) Posts Earnings in Q4, Revenues Top Estimates
finance.yahoo.com - February 28 at 9:09 AM |
| Penumbra Inc (PEN) Shares Bought by Schwab Charles Investment Management Inc.
www.americanbankingnews.com - February 28 at 5:45 AM |
| Penumbra, Inc. to Host Earnings Call
finance.yahoo.com - February 27 at 5:13 PM |
| Penumbra, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 27 at 5:13 PM |
| Carillon Tower Advisers Inc. Acquires New Position in Penumbra Inc (PEN)
www.americanbankingnews.com - February 27 at 5:32 AM |
 | Is a Surprise Coming for Penumbra (PEN) This Earnings Season?
www.zacks.com - February 26 at 9:08 AM |
| Is Penumbra Inc (NYSE:PEN) An Industry Laggard Or Leader?
finance.yahoo.com - February 23 at 9:10 AM |
| William Blair Comments on Penumbra Inc's FY2017 Earnings (PEN)
www.americanbankingnews.com - February 23 at 8:24 AM |
| Penumbra Has Challenged The 'Paradigm' Of Stroke Treatment; William Blair Initiates At Outperform
finance.yahoo.com - February 22 at 9:06 AM |
 | Afghan tradition helps strangers become friends over dinner
www.msn.com - February 21 at 4:50 PM |
| Penumbra (PEN) Research Coverage Started at William Blair
www.americanbankingnews.com - February 21 at 10:58 AM |
| Key Factors to Influence Penumbra's (PEN) Earnings in Q4
finance.yahoo.com - February 21 at 9:15 AM |
| Penumbra Inc (PEN) Expected to Post Earnings of -$0.01 Per Share
www.americanbankingnews.com - February 19 at 1:16 AM |
| Should You Buy Penumbra Inc (NYSE:PEN) At $93.6?
finance.yahoo.com - February 15 at 4:44 PM |
Penumbra (NYSE:PEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Penumbra (NYSE:PEN) Income Statement, Balance Sheet and Cash Flow Statement
Penumbra (NYSE PEN) Stock Chart for Saturday, April, 21, 2018
Loading chart…
